FDA and psilocybin · Updated November 2026
COMP360 and FDA approval: what it would mean in Colorado
COMP360 is Compass Pathways’ synthetic psilocybin for treatment-resistant depression. Compass finished filing its FDA application on November 9, 2026, and no psilocybin product is FDA-approved yet. An approval would create a prescription drug for one condition. Colorado’s healing centers operate under a separate state program.
Questions about psilocybin therapy now?
Send a note and we’ll reach out to talk through how psilocybin therapy works in Colorado today and whether it fits.
Prefer to talk? Call (720) 734-8080.
The basics
What is COMP360?
COMP360 is a synthetic, crystalline form of psilocybin made in a lab by Compass Pathways, a publicly traded drug company. It has the same active compound found in psilocybin mushrooms, produced as a pharmaceutical.
Compass is developing it for treatment-resistant depression, meaning depression that hasn’t responded well enough to earlier treatments. In Compass’s trials, participants took COMP360 with psychological support before, during and after the dose.
The FDA gave COMP360 Breakthrough Therapy designation for treatment-resistant depression in 2018. That designation speeds up the review process for a specific investigational drug. It isn’t an approval, and it doesn’t apply to psilocybin in general.
The timeline
Where does COMP360's FDA review stand?
- November 2022. A Phase 2b trial of 233 people with treatment-resistant depression was published in the New England Journal of Medicine.
- June 2025. The first Phase 3 trial, COMP005, met its primary goal.
- February 2026. The second Phase 3 trial, COMP006, met its primary goal.
- April 2026. The FDA agreed to review Compass’s application in parts as it was submitted.
- November 9, 2026. Compass completed its new drug application.
Compass has said it expects to launch in the first half of 2027, but that depends on FDA approval and on the Drug Enforcement Administration moving the drug out of Schedule I. Compass described that timeline in its November 2026 SEC filing. Neither step has happened yet.
The research
What did the COMP360 trials show?
Compass has run three controlled trials in treatment-resistant depression, with more than 1,000 participants combined:
- Phase 2b (233 people). A single 25 mg dose reduced depression scores more than a 1 mg dose at three weeks. The 10 mg dose didn’t separate from 1 mg.
- COMP005 (258 people). A single 25 mg dose reduced depression scores by 3.6 points more than placebo at six weeks, on a 60-point scale.
- COMP006 (581 people). Two 25 mg doses three weeks apart reduced scores by 3.8 points more than two 1 mg doses at six weeks. Compass reported that 39% of people in the 25 mg group had a meaningful drop in symptoms by week six.
The limits
The Phase 3 results so far come mainly from Compass’s own announcements, and full peer-reviewed papers are still to come. A difference of about four points is modest in absolute terms, though some researchers have noted it’s in line with other treatments for this hard-to-treat group.
These trials studied one synthetic formulation in people with treatment-resistant depression. They don’t tell us how psilocybin performs for other conditions or in other settings.
If it's approved
What would FDA approval of COMP360 change?
If the FDA approves COMP360, here’s what would follow:
- A prescription drug would exist. It would be approved for treatment-resistant depression, the condition it was studied for.
- The FDA would set the conditions. Its label would spell out who can receive it and how it’s given.
- Federal rescheduling would still be needed. Compass has said the DEA must reschedule the drug before it can be sold.
- Colorado is already set up for it. A 2025 state law, House Bill 25-1063, lets an FDA-approved prescription drug containing crystalline polymorph psilocybin be prescribed in Colorado.
What stays the same
What wouldn't change for Colorado healing centers?
Colorado’s healing centers run under state law, separate from the FDA process. The sponsors of House Bill 25-1063 said it wasn’t meant to change the state’s regulated natural medicine program.
- Adults 21 and older could still receive psilocybin at a licensed healing center without a diagnosis or prescription.
- Healing centers would still use psilocybin from state-licensed Colorado businesses, not COMP360.
- The state’s structure of preparation, a supervised dosing session (the state calls it an administration session) and integration would stay in place.
Read how Colorado law treats psilocybin at healing centers today.
Side by side
How is COMP360 different from psilocybin therapy at a healing center?
| COMP360 | Psilocybin at a Colorado healing center | |
|---|---|---|
| Status | Investigational; FDA decision pending | Legal under Colorado law since 2025 |
| Who it’s for | If approved, people prescribed it for treatment-resistant depression | Adults 21 and older; no diagnosis required |
| The psilocybin | Synthetic, lab-made formulation | Psilocybin from state-licensed Colorado businesses |
| Where it’s given | To be set by the FDA if approved | A state-licensed healing center |
| Support around the dose | Psychological support in trials; final requirements set by the FDA | Required preparation, a supervised dosing session and integration |
At our Denver center, that support comes from licensed therapists and a psychiatric nurse practitioner. Our founder holds Colorado’s Clinical Facilitator license, and the rest of the team holds the state’s facilitator training license.
Deciding
Should you wait for COMP360?
That depends on your situation, and it’s worth talking through with the clinician who treats your depression now. An approval isn’t certain, and the timing could move.
If you’re considering psilocybin therapy now, our safety screening looks at your health, your mental health history and the medications you take. See how psilocybin therapy works at our center, or meet the clinicians who facilitate here. We’re in central Denver, just off I-25 and Evans.
FAQ
Questions about COMP360 and the FDA
No. As of November 2026, the FDA hasn't approved any psilocybin product. Compass Pathways completed its application for COMP360 on November 9, 2026, and the FDA's decision is pending.
Compass has said it expects a launch in the first half of 2027 if the FDA approves it and the DEA reschedules it. Neither step is certain, and the timing could change.
It's the same active compound in a different form. COMP360 is a synthetic, crystalline formulation made in a lab. Colorado healing centers use psilocybin from state-licensed Colorado businesses.
Yes. Under Colorado law, adults 21 and older can receive psilocybin at a state-licensed healing center now, after a safety screening and preparation. COMP360's FDA review doesn't change that.
Schedule your journey
Ready to talk about psilocybin therapy?
Tell us a little about yourself and what you’re hoping for. We’ll reach out to talk through fit, packages and scheduling.
Our healing center is at 4155 E Jewell Ave #405, Denver, CO 80222, just off I-25 and Evans.
Prefer to talk? Call (720) 734-8080.
Schedule your journey
Our licensed therapists and psychiatric nurse practitioner are scheduling psilocybin-assisted therapy sessions in Denver, just off I-25 and Evans.